BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 34093441)

  • 1. Case Report: Unmasking Hypercalcemia in Patients With Neuroendocrine Neoplasms. Experience From Six Italian Referral Centers.
    Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Guarnotta V; Ragni A; Zanata I; Colao A; Faggiano A
    Front Endocrinol (Lausanne); 2021; 12():665698. PubMed ID: 34093441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1,25-dihydroxyvitamin D and PTHrP mediated malignant hypercalcemia in a seminoma.
    Rodríguez-Gutiérrez R; Zapata-Rivera MA; Quintanilla-Flores DL; Camara-Lemarroy CR; Lavalle-Gonzalez FJ; González-González JG; Villarreal-Pérez JZ
    BMC Endocr Disord; 2014 Apr; 14():32. PubMed ID: 24721620
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peptide receptor radionuclide therapy controls inappropriate calcitriol secretion in a pancreatic neuro-endocrine tumor: a case report.
    Haemels M; Delaunoit T; Van Laere K; Van Cutsem E; Verslype C; Deroose CM
    BMC Gastroenterol; 2020 Oct; 20(1):324. PubMed ID: 33008295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What Lies behind Paraneoplastic Hypercalcemia Secondary to Well-Differentiated Neuroendocrine Neoplasms? A Systematic Review of the Literature.
    Giannetta E; Sesti F; Modica R; Grossrubatscher EM; Ragni A; Zanata I; Colao A; Faggiano A
    J Pers Med; 2022 Sep; 12(10):. PubMed ID: 36294693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe hypercalcemia due to metastatic pancreatic neuroendocrine tumor: a case report.
    Behdadnia A; Jeddi M
    J Med Case Rep; 2023 Sep; 17(1):400. PubMed ID: 37670372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PTHrP, calcitonin and calcitriol in a case of severe, protracted and refractory hypercalcemia due to a pancreatic neuroendocrine tumor.
    Van den Eynden GG; Neyret A; Fumey G; Rizk-Rabin M; Vermeulen PB; Bouizar Z; Body JJ; Dirix LY
    Bone; 2007 Apr; 40(4):1166-71. PubMed ID: 17188588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal of Severe and Refractory Humoral Hypercalcemia With 177Lu-Octreotate Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumor of the Pancreas.
    Iliuta IA; Beauregard JM; Couture F; Douville P; Mac-Way F
    Clin Nucl Med; 2015 Sep; 40(9):e448-50. PubMed ID: 26053724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignant hypercalcaemia related to parathyroid hormone-related peptide (PTHrP) secretion from a metastatic pancreatic neuroendocrine tumour (NET).
    Symington M; Davies L; Kaltsas G; Weickert MO
    BMJ Case Rep; 2017 Mar; 2017():. PubMed ID: 28331027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laryngeal Neuroendocrine Tumor With Elevated Serum Calcitonin: A Diagnostic and Therapeutic Challenge. Case Report and Review of Literature.
    Feola T; Puliani G; Sesti F; Modica R; Biffoni M; Di Gioia C; Carletti R; Anastasi E; Di Vito V; Centello R; Lenzi A; Isidori AM; Faggiano A; Giannetta E
    Front Endocrinol (Lausanne); 2020; 11():397. PubMed ID: 32765421
    [No Abstract]   [Full Text] [Related]  

  • 10. Parathyroid hormone-related peptide (PTHrP) secretion by gastroenteropancreatic neuroendocrine tumors (GEP-NETs): clinical features, diagnosis, management, and follow-up.
    Kamp K; Feelders RA; van Adrichem RC; de Rijke YB; van Nederveen FH; Kwekkeboom DJ; de Herder WW
    J Clin Endocrinol Metab; 2014 Sep; 99(9):3060-9. PubMed ID: 24905065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unusual complication of a pancreatic neuroendocrine tumor presenting with malignant hypercalcemia.
    Kanakis G; Kaltsas G; Granberg D; Grimelius L; Papaioannou D; Tsolakis AV; Öberg K
    J Clin Endocrinol Metab; 2012 Apr; 97(4):E627-31. PubMed ID: 22319031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting neuroendocrine tumors. Report of six cases.
    Milanesi A; Yu R; Wolin EM
    Pancreatology; 2013; 13(3):324-6. PubMed ID: 23719609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
    Müssig K; Petersenn S; Wehrmann M; Horger M; Vierling P; Häring HU; Gallwitz B
    Eur J Gastroenterol Hepatol; 2007 Aug; 19(8):719-23. PubMed ID: 17625444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypercalcemia of malignancy caused by parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumors (PTHrP-PNETs): Case Report.
    Pitts S; Mahipal A; Bajor D; Mohamed A
    Front Oncol; 2023; 13():1197288. PubMed ID: 37377908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypercalcemia in non-Hodgkin's lymphoma due to cosecretion of PTHrP and 1,25-dihydroxyvitamin D.
    Gonciulea AR; Wang Y; Bikle DD; Sellmeyer DE
    Osteoporos Int; 2021 Dec; 32(12):2587-2592. PubMed ID: 34230999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia.
    Endo K; Katsumata K; Iguchi H; Kubodera N; Teramoto T; Ikeda K; Fujita T; Ogata E
    J Bone Miner Res; 1998 Sep; 13(9):1378-83. PubMed ID: 9738509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Case report: lanreotide in the management of hypercalcemia of malignancy.
    Anthony LB; May ME; Oates JA
    Am J Med Sci; 1995 Jun; 309(6):312-4. PubMed ID: 7771500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parathyroid hormone-related protein induced coupled increases in bone formation and resorption markers for 7 years in a patient with malignant islet cell tumors.
    Takeuchi Y; Fukumoto S; Nakayama K; Tamura Y; Yanagisawa A; Fujita T
    J Bone Miner Res; 2002 May; 17(5):753-7. PubMed ID: 12009004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review.
    Srirajaskanthan R; McStay M; Toumpanakis C; Meyer T; Caplin ME
    Neuroendocrinology; 2009; 89(1):48-55. PubMed ID: 18679021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of cinacalcet and sunitinib to treat hypercalcaemia due to a pancreatic neuroendocrine tumor.
    Valdes-Socin H; Almanza MR; Fernández-Ladreda MT; Daele DV; Polus M; Chavez M; Beckers A
    Arch Endocrinol Metab; 2017; 61(5):506-509. PubMed ID: 28977163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.